Eventide Asset Management, LLC Rocket Pharmaceuticals, Inc. Transaction History

Eventide Asset Management, LLC

$5.22 Billion
Q4 2024

A detailed history of Eventide Asset Management, LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Eventide Asset Management, LLC holds 770,691 shares of RCKT stock, worth $8.07 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

770,691

Previous 770,691 -0.0%

Holding current value

$8.07 Million

Previous $14.2 Million 31.94%

% of portfolio

0.19%

Previous 0.25%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$20.66 - $26.72 $5.78 Million - $7.48 Million	279,959 Added 57.05%	770,691 $16.6 Million
Q4 2023 Feb 14, 2024	SELL	$16.78 - $31.94 $6.83 Million - $13 Million	-407,268 Reduced 45.35%	490,732 $14.7 Million
Q1 2023 May 15, 2023	BUY	$15.79 - $22.6 $6.75 Million - $9.66 Million	427,346 Added 90.8%	898,000 $15.4 Million
Q4 2022 Feb 13, 2023	BUY	$15.5 - $22.76 $7.3 Million - $10.7 Million	470,654 New	470,654 $9.21 Million
Q4 2020 Feb 16, 2021	SELL	$23.3 - $59.57 $36.1 Million - $92.3 Million	-1,550,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$13.32 - $22.61 $1.8 Million - $3.05 Million	135,000 Added 9.54%	1,550,000 $32.4 Million
Q3 2019 Nov 21, 2019	BUY	$10.85 - $14.78 $4.56 Million - $6.22 Million	420,686 Added 42.31%	1,415,000 $16.5 Million
Q2 2019 Aug 14, 2019	BUY	$15.0 - $19.81 $4.29 Million - $5.66 Million	285,714 Added 40.32%	994,314 $14.9 Million
Q4 2018 Feb 14, 2019	BUY	$11.21 - $23.53 $3.52 Million - $7.39 Million	314,015 Added 79.58%	708,600 $10.5 Million
Q1 2018 May 15, 2018	BUY	$11.68 - $19.19 $4.61 Million - $7.57 Million	394,585 New	394,585 $7.4 Million

Others Institutions Holding RCKT

# of Institutions

244

Shares Held

108M

Call Options Held

262K

Put Options Held

159K

View Full List

About ROCKET PHARMACEUTICALS, INC.

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $792M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

More about RCKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eventide Asset Management, LLC with notifications on news.

Account

Eventide Asset Management, LLC Rocket Pharmaceuticals, Inc. Transaction History